Scott Victoria, Williams Ryan J, Levi Daniel S
Division of Pediatric Cardiology, David Geffen School of Medicine at UCLA, B2-427 MDCC, 10833 Le Conte Ave, Los Angeles, CA 90095-1743, USA.
Pediatr Cardiol. 2011 Jun;32(5):615-20. doi: 10.1007/s00246-011-9928-5. Epub 2011 Mar 6.
Despite aggressive immunosuppressive therapy, pediatric orthotopic heart transplant (OHT) candidates with elevated pre-transplant panel reactive antibody (PRA) carry an increased risk of rejection and early graft failure following transplantation. This study has aimed to more specifically evaluate the outcomes of transplant candidates stratified by PRA values. Records of pediatric patients listed for OHT between April 2004 and July 2008 were reviewed (n = 101). Survival analysis was performed comparing patients with PRA < 25 to those with PRA > 25, as well as patients with PRA < 80 and PRA > 80. Patients with PRA > 25 had decreased survival compared with those with PRA < 25 after listing (P = 0.004). There was an even greater difference in survival between patients with PRA > 80 and those with PRA < 80 (P = 0.002). Similar analyses for the patients who underwent successful transplantation showed no significant difference in post-transplant survival between patients with a pre-transplant PRA > 25 and those with PRA < 25 (P = 0.23). A difference approaching significance was noted for patients with PRA > 80 compared with PRA < 80 (P = 0.066). Patients with significantly elevated pre-transplant PRAs at the time of listing have a significantly worse outcome compared to those with moderately increased PRA values or non-sensitized patients. Further study is necessary to guide physician and family treatment decisions at the time of listing.
尽管采用了积极的免疫抑制治疗,但移植前群体反应性抗体(PRA)升高的小儿原位心脏移植(OHT)候选者在移植后发生排斥反应和早期移植物失败的风险增加。本研究旨在更具体地评估按PRA值分层的移植候选者的结局。回顾了2004年4月至2008年7月期间登记等待OHT的小儿患者记录(n = 101)。进行生存分析,比较PRA < 25的患者与PRA > 25的患者,以及PRA < 80和PRA > 80的患者。登记后,PRA > 25的患者与PRA < 25的患者相比,生存率降低(P = 0.004)。PRA > 80的患者与PRA < 80的患者之间的生存率差异更大(P = 0.002)。对成功进行移植的患者进行的类似分析显示,移植前PRA > 25的患者与PRA < 25的患者在移植后的生存率无显著差异(P = 0.23)。与PRA < 80的患者相比,PRA > 80的患者差异接近显著(P = 0.066)。与PRA值中度升高的患者或未致敏患者相比,登记时移植前PRA显著升高的患者结局明显更差。有必要进行进一步研究,以指导医生和家属在登记时做出治疗决策。